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Abstract 
Objectives: Modern medical practice strives for a personalized approach to patient care. The 
evidence regarding prevalence of endometrial cancer in various ethnic groups is scarce and 
conflicting. This study was conducted to determine this in postmenopausal bleeding (PMB) 
women. 
Methods: Prospectively collected data of 1995 women attending PMB clinic over a 4-year 
period. Women were grouped according to self-assigned ethnicity into “White”, “Black”, 
“South Asian” and “Others”, and according to investigation results into group 1-benign 
findings and group 2-hyperplasia or cancer. 
Results: The adjusted odds ratio (95% CI) for Black ethnicity was 0.35 (0.17-72; p=0.001). 
This means that Black women had 65% (28%-83%) less odds for developing endometrial 
hyperplasia and cancer compared to White women, independent from other predictors. 
Comparing to White ethnicity, women in all ethnic groups were significantly younger at 
presentation with PMB, had shorter duration since last menopausal bleeding (LMP), and less 
likely to be diabetic (p<0.001). 
Conclusion: This study found significantly lower prevalence of endometrial cancer in the 
Black race in PMB women population; a finding that cannot be readily explained by other 
known risk factors. Further research is warranted to confirm the results and explore the 
underlying etiology. 
 
Keywords  
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Introduction 
Non-White ethnic groups comprise around 14.1% of the English and Welsh population, the 
largest group being South Asians (Indians, Pakistanis and Bangladeshis), followed by Blacks 
(Black Africans and Black Caribbean) and Chinese [1]. However; data on the incidence of 
cancers by ethnic group remains scarce, particularly that of endometrial cancer [2]. National 
Cancer Intelligence Network (NCIN, England, 2002-2006) statistics revealed that the rates of 
endometrial cancer in women aged ≥ 65 years were statistically significantly lower in Asian 
and non-significantly higher in black (incidence rate ratio = 1.16) when compared with White 
women. Results were inconclusive for women <65 years of age. However; these data were 
criticized because of high volume of missing ethnicity data; 6005/27680 (22%) [2, 3]. On the 
other hand, many population-based studies revealed lower prevalence of endometrial cancer 
and higher mortality rates in African Americans [4, 5, 6]. 
 
There are few studies in the literature aimed to fit predictions model to predict the 
development of endometrial hyperplasia and cancer in women with postmenopausal bleeding 
(PMB) using the demographic and clinical characteristics like age, body mass index (BMI) 
and endometrial thickness. However, none of these studies used ethnicity as an input 
parameter, and a systematic review of published prediction models did not discuss the 
relevance of ethnicity to endometrial cancer [7]. In the era of precision medicine, aiming to 
offer a personalized approach to patient care, information about the association between 
ethnicity and endometrial cancer would be helpful to develop targeted strategies for cancer 
prevention and potentially better identify communities at risk [8, 9]. This is particularly 
important in women with PMB who represent the highest risk group. Given the scarcity of 
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information in this area, this study was conducted to determine the association between 
ethnicity and the rate of developing endometrial hyperplasia and cancer in women with PMB. 
Since our Cancer Centre serves a district with diverse multi-ethnic population, it was deemed 
optimal to evaluate such an association. 
 
Materials and methods 
The routine demographic and clinical data of the PMB clinic were prospectively collected in 
a specially designed Microsoft Access database, then extracted anonymously and compiled 
on an Excel spreadsheet. The database contained the details of 1995 consecutive women 
reviewed at Sandwell and West Birmingham Hospitals NHS Trust, UK between 1st January 
2011 and 31st January 2015. The investigations results were accessed using the hospital 
electronic “Clinical Data Archive”. PMB was defined as an episode of vaginal bleeding 
occurring ≥ 12 months after cessation of menstruation in women aged ≥45 years. Women 
were managed according to an evidence-based PMB protocol as described in previous studies 
[10-12]. The ethnicity data were collected by self-assignment during the consultation as per 
categories recommended by the Office of National Statistics [13]. For the purposes of the 
study, ethnicity was categorized into four groups: (1) White; including White British and 
other Whites, (2) Black; including Black Caribbean and Black Africans, (3) South Asian; 
including Indians, Bangladeshis and Pakistanis, and (4) Others; including Middle Eastern, 
Asian others and Mixed [2]. Women were further categorized according to the investigation 
results into: group 1 - benign finding, and group 2 - endometrial hyperplasia or cancer. 
The ethnic distribution of the population in the district served by the Trust is 61.9% White, 
7.6% Black, 22.5% South Asian, and 8% Others [14]. During the study period, the ethnic 
distribution of women attending the hospital in all departments was 48.9% White, 11.6% 
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Black, 22% South Asian, and 17.5% Others. The ethnic distribution of our PMB cohort was 
65% White, 13% Black, 14% South Asian, and 8% Others. Data were collected as part of the 
routine treatment, and the project was considered as "service evaluation"; therefore, ethics 
approval was not deemed necessary. Service evaluation does not require ethical approval in 
the UK [15, 16]. 
 
Statistical analyses were carried out using Minitab© version 18 statistical package software 
(Pennsylvania State University, Pennsylvania, USA). Distribution of continuous variables 
was determined by Anderson-Darling and Kolmogorov-Smirnov tests. When normally 
distributed, they were presented as mean with standard deviation. When not normally 
distributed, they were presented as median with interquartile range. Differences between two 
outcome groups were sought by t test or the Mann-Whitney test, while differences in four 
ethnic groups were sought by analysis of variance (or the Kruskal-Wallis test) as demanded 
by distribution. Inter-group differences were sought by Tukey’s test. Differences in 
categorical indices were sought by the Chi-squared test (Tables 1 and 2) with adjustment by 
family-wise error rate for multiple analyses. A Multivariable binomial logistic regression 
analysis (MVLRA) was used to identify the independent predictors of endometrial 
hyperplasia and cancer. Univariate factors linked to outcome were selected for the MVLRA. 
With several indices in the analysis, we selected those factors with a more stringent p<0.02 
i.e. age, time since LMP, BMI, endometrial thickness and ethnicity. HRT, hypertension and 
other factors were not part of the model as they were not linked to outcome (Table 3 and 4). 
Data with a non-normal distribution were log transformed. p<0.05 was considered 
statistically significant. 
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Results 
Clinical and demographic data of the 1995 women are shown in Table 1. Comparing the 
groups, there was a difference in age (ANOVA p<0.001) and time since last LMP (ANOVA 
p<0.001) with the White women being older and having a longer time since LMP than the 
three other groups (all p<0.05, Tukey’s test). The groups were matched for BMI (ANOVA 
p=0.071), but not hypertension with Black women being more likely to be hypertensive 
(adjusted p=0.01) compared to the White women, or the use of HRT with Black and South 
Asian women being less likely to use HRT than White women (adjusted p=0.045 and 
p=0.003, respectively). There was a difference in the incidence of diabetes, with White 
women being more likely to be diabetic than the three other groups (each adjusted Chi-
squared p<0.003). There was no difference in the use of tamoxifen (Chi-squared p=0.197) or 
in endometrial thickness (Kruskal-Wallis p=0.301). Table 2 shows outcomes and histological 
subtypes.  
 
One hundred and ninety-seven (10%) of the women had endometrial hyperplasia and cancer. 
Compared to White ethnicity, Black women had a significantly lower prevalence of 
endometrial hyperplasia and cancer (Chi-squared p<0.01), and of endometrial cancer alone 
(Chi-squared p<0.02). Analyzing for type of cancer, Black women had a higher rate of non-
endometrioid cancer (n=6, 67%) compared to White women (n=26, 27%)(Chi-squared p 
=0.015). In determining those factors with a potential to predict endometrial hyperplasia and 
cancer, Table 3 shows analysis of clinical and demographic data according to outcome (i.e. 
endometrial hyperplasia and cancer, or free of these conditions). It showed that age, ethnicity, 
time since LMP, BMI and endometrial thickness all predicted outcome with p<0.02.  
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These five univariate predictors were fed into MVLRA (Table 4). Only Black ethnicity and 
endometrial thickness independently predicted the risk of endometrial hyperplasia and 
cancer. The adjusted odds ratio (95% CI) for Black ethnicity was 0.35 (0.17-0.72; p=0.001). 
This means that Black women had 65% (28%-83%) less odds for developing endometrial 
hyperplasia and cancer compared to White women, independent from other predictors. When 
compared to “White”, “South Asian” and “Other” ethnic groups did not show any statistically 
significant association between the ethnicity and the outcome.  
 
The statistical analysis was repeated after removing the oldest 125 women (9.7%) until the 
ages of various ethnic groups are no longer significantly different to each other. Based on this 
sub analysis of 1866 women, endometrial thickness and Black ethnicity were still 
independent predictors of endometrial hyperplasia and cancer (both p<0.001). When 
compared to White women, the odds ratio (95% CI) for endometrial hyperplasia and cancer 
in Black women was 0.35 (0.17-0.72). Thus, the adjusted odd ratios produced from the 
MVLRA were exactly the same when the ages of the four groups was not significantly 
different, negating a role of this potential confounder. 
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Discussion 
To our knowledge, this is the first study to quantify the risk of endometrial hyperplasia and 
cancer according to ethnicity in PMB women population. This study found that Black women 
had 65% lower risk to develop endometrial hyperplasia and cancer when compared to White 
women. There was no statistically significant difference between “White”, “South Asian” and 
“Other” ethnic groups. Grouping endometrial hyperplasia and cancer had not affected the 
results since Black women showed also significantly lower prevalence of endometrial cancer 
alone when compared to White women. Similar findings were obtained from population-
based studies. Farley et al found that the incidence of endometrial cancer in African 
Americans was 30% lower and the mortality rate 80% higher when compared to Whites [4].  
 
A report of “The Surveillance, Epidemiology, and End Results, SEER” program data, 
including 1844 African American and 16512 Caucasian women, found the incidence of 
endometrial cancer in African Americans to be 65% of that in Caucasians, while the rates of 
aggressive subtypes (serous and clear cell adenocarcinomas and sarcomas) were doubled in 
African Americans [17]. Another report of SEER analysis by Cote et al showed that the age-
adjusted incidence rates for all types-endometrial cancer is less in non-Hispanic black (NHB) 
compared to non-Hispanic white (NHW). (RR=0.81, 95% CI=0.8-0.83, p<0.0001), while the 
incidence of serous endometrial cancer is higher in the NHB (RR=2.19, 95%CI=2.05-2.33, 
p<0.0001). Further, the annual percentage change for the NHB was significantly higher than 
that of NHW (2.5 v 0.6) [18].This was also shown in another cohort study where the 
incidence in African Americans was 76% of that in Whites, but African American rates of 
aggressive subtypes was >3 times higher [6]. Nonetheless, the national statistics in England 
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revealed that the rates of endometrial cancer in women aged ≥ 65 years were non-
significantly higher in black when compared with White women [3]. 
 
In this study and the other population-based studies [6], adjustment for other confounders did 
not explain the observed lower risk among Back women. While the differences in risk 
between ethnic groups could be attributed to the groups themselves, it may also be attributed 
to a deleterious germline mutation or a widespread environmental exposure [8].  
 
The strength of the present study is that the data were collected prospectively, consecutively, 
and in a standardized fashion, with no missing ethnicity data. The use of self-assigned 
ethnicity was one of the major strengths since it is more accurate than other older systems 
such as name analysis [2]. In addition, this cohort is relatively homogeneous including only 
women presented with PMB who represent the highest risk group for endometrial cancer. 
However, the relatively small sample size did not allow for subgroup analysis.  
 
The terms South Asian and Black encompass a number of more specific ethnicities, each with 
their own unique lifestyle, culture and characteristics. Shirley et al found strong evidence of 
intra-ethnic differences in the South Asian group, with rates among Bangladeshis <50% that 
of Indians, Pakistanis or Whites. The lower prevalence of obesity, high parity, and higher 
initiation of breastfeeding among Bangladeshis may contribute to these differences. There 
was no difference observed between Black Africans and Black Caribbean [2]. Similar to 
population-based studies [2, 8], one recognized challenge in interpreting our findings is the 
absence of data on nativity for each patient. Women were classified according to ethnicity 
rather than specific country of origin; hence it was not feasible to evaluate differences 
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between women who are foreign-born versus UK-born. Determining these differences may 
be relevant to disease development. In addition, in this cohort, the tamoxifen usage was 
higher in White women (4.4%) when compared with Black (1.2%). However; the univariate 
analysis showed no effect of tamoxifen usage on the outcomes, and the logistic regression 
model approach, to control for the effect of tamoxifen on the outcome, showed insignificant 
adjusted odds ratio. This might be attributed to the small sample size of the Black ethnic 
group.  
 
Another weakness in this study is the lack of information about the type of hormonal 
replacement therapy (HRT) used. Although Black women were significantly (adjusted 
p=0.045) less likely to use HRT (6%) when compared to White women (11.5%), it is not 
known whether they used more of continuous combined HRT, which is recognized to be 
protective to the endometrium, rather than sequential HRT. 
 
The endometrial hyperplasia and cancer group is indeed small relative to the benign 
endometrium group and thus very unbalanced, but this is to be expected in every day 
practice. Therefore, it was preferred not to perform a nested study with only a randomly 
selected 175 women in the benign endometrium group. However, despite the small sample, 
we have full confidence in the predictors of endometrial hyperplasia and cancer at p<0.001 
and p=0.002. Had these values been closer to 0.05, it would have been concerning. 
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Conclusion 
The results of this study suggest significantly lower prevalence of endometrial cancer in the 
Black race in PMB women population. This finding cannot be readily explained by known 
risk factors. As oncology continues to strive for a precise personalized approach to patient 
care, further research is warranted to confirm the findings and explore the underlying 
etiology. 
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Tables legends  
Table 1: Women characteristics grouped by ethnicity (n=1995) 
Table 2: Histopathological subtypes of the outcomes (n=1995) 
Table 3: Univariate predictors of outcome 
Table 4: Results of the multivariable logistic regression analysis 
 
 Table 1: Women characteristics grouped by ethnicity (n=1995) 
Variable 
White 
1288 (65%) 
Black 
264 (13%) 
South Asian 
280 (14%) 
Other 
163 (8%) 
Total 
n=1995 
Age (years) 62.1 (11.3) 58.5 (10.5)* 59.2 (9.1)* 58.2 (8.7)* 60.9 (10.8) 
Duration since LMP (years) 10 (3-20) 6 (2-19)* 8 (3-15)* 6 (3-12)* 8 (3-20) 
BMI (kg/m2) 29.9 (8.9) 31.3 (8.3) 30.3 (7.3) 29.7 (7.8) 30.8 (7.3) 
HRT users (n, %) 148 (11.5%) 17 (6%)*a 13 (5%)*b 13 (7%) 191 (9.6%) 
Hypertension (n, %) 526 (41%) 134 (51%)*c 133 (48%) 67 (41%) 860 (43.1%) 
Diabetes (n, %) 161 (8%) 71 (4%)*d 98 (5%)*d 39 (2%)*d 369 (18.5%) 
Tamoxifen users (n, %) 57 (4.4%) 5 (1.2%) 8 (3%) 6 (3.7%) 76 (3.8%) 
Endometrial thickness (mm) 4.5 (2.7-8) 4.5 (2.5-8) 5 (2.7-10) 5 (2.8-10) 5 (3-9) 
BMI=Body Mass Index   HRT=Hormone Replacement Therapy   LMP=Last menstrual period 
Normally distributed continuous variable data (Age and BMI) presented as mean (SD) and analysed by ANOVA, while not normally 
distributed continuous data (duration since LMP and endometrial thickness) are presented as median (inter-quartile range) and 
analysed by Kruskal-Wallis. 
*p<0.05 Tukey’s test, duration since LMP log transformed. 
 Categorical data (HRT use, diabetes, hypertension, diabetes, and Tamoxifen use) are presented as n (%), and analysed by Chi-squared 
test, and adjusted for family-wise error rate versus White women; ap=0.045,  bp=0.003,  cp=0.01,  dp<0.003.  
 Table 2: Histopathological subtypes of the outcomes (n=1995) 
Histopathological Subtype White 
1288 (64.4%) 
Black 
264 (13.2%) 
South Asian  
280 (14%) 
Other 
163 (8.2%) 
Total  
n=1995 
Group 1 (benign findings) 1150 (89.3%) 253 (95.8%) 251 (89.6%) 144 (88.3%) 1798 (90.1%) 
Group 2 (endometrial 
hyperplasia and cancer) 
138 (10.7%) 11 (4.2%) 29 (10.4%) 19 (11.7%) 197 (9.9%) 
Endometrial non-atypical 
hyperplasia 
19 (1.5%) 0 (0%) 5 (1.8%) 0 (0%) 24 (1.2%) 
Endometrial atypical 
hyperplasia 
24 (1.9%) 2 (0.8%) 5 (1.8%) 4 (2.5%) 35 (1.8%) 
Endometrial cancer 95 (7.4%) 9 (3.4%) 19 (6.8%) 15 (9.2%) 138 (6.9%) 
Endometrioid 69 (5.4%) 3 (1.1%) 13 (4.6%) 9 (5.5%) 94 (4.7%) 
Non-endometrioid 26 (2%) 6 (2.3%) 6 (2.1%) 6 (3.7%) 44 (2.2%) 
Serous 18 (1.4%) 6 (2.3%) 3 (1.1%) 3 (1.8%) 30 (1.5%) 
Others 8 (0.6%) 0 (0%) 3 (1.1%) 3 (1.8%) 14 (0.7%) 
Others=Other types of non-endometrioid endometrial cancer including clear cell carcinoma, squamous cell carcinoma and endometrial sarcoma. 
All data are presented as n(%).  
 Table 3: Univariate predictors of outcome 
 Group 1: benign findings  
(n=1798, 90%) 
Group 2: endometrial hyperplasia 
and cancer (n=197, 10%) 
p value 
Age (years) 60.4 (10.7) 65.4 (10.6) <0.001* 
Ethnicity (n, %) 
White 
Black 
South Asian 
Other 
 
1150 (89.3%) 
253 (95.8%) 
251 (89.6%) 
144 (88.3%) 
 
138 (10.7%) 
11 (4.2%) 
29 (10.4%) 
19 (11.7%) 
 
 
0.01* 
Time since LMP (years) 8 (3-20) 14.5 (6-20) <0.001* 
BMI (kg/m2) 30.6 (7.2) 33.0 (8.1) <0.001* 
HRT use (n, %) 180 (10%) 11 (5.6%) 0.045 
Hypertension (n, %) 754 (42%) 91 (46.2%) 0.251 
Diabetes (n, %) 327 (18.2%) 42 (21.3%) 0.282 
Tamoxifen use (n, %) 71 (4%) 5 (2.54%) 0.326 
Endometrial thickness (mm) 4.5 (3-8) 13.3 (9-20) <0.001* 
 
 BMI=Body Mass Index  HRT=Hormone Replacement Therapy  LMP=Last menstrual period 
Normally distributed continuous variable data (Age and BMI) presented as mean (SD), while not normally distributed continuous data 
(duration since LMP and endometrial thickness) are presented as or median (inter-quartile range). 
Categorical data (HRT use, diabetes, hypertension, diabetes, and Tamoxifen use) are presented as n (%). 
*p<0.05 compared to group 2; p value is produced from t test applied for normally distributed continuous data, Mann-Whitney U test 
applied for not normally distributed continuous data, and Chi-squared test applied for categorical data. 
Variables (Age, duration since LMP, ethnicity, BMI, and endometrial thickness) were selected to be fed into the multivariable logistic 
regression analysis as p value was<0.02. 
  
 Table 4: Results of the multivariable logistic regression analysis 
Predictor Adjusted odds ratio 95% confidence interval p value 
Age 1.02 0.99-1.04 0.200 
Duration since LMP 1.14 0.87-1.5 0.352 
BMI 1.01 0.99-1.04 0.278 
Endometrial thickness 8.45 6.16-11.63 <0.001* 
Ethnicity    0.016* 
White Reference Reference  
Black 0.35 0.17-0.72  
South Asians 0.8 0.48-1.34  
Others 1.02 0.55-1.88  
BMI=Body Mass Index    LMP=Last menstrual period 
Age and BMI are normally distributed, no variable transformation required before the regression analysis. 
Duration since LMP and Endometrial thickness were log transformed for analysis as they are not normally distributed. 
